Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Adelis and other shareholders in connection with the sale of Logent
Mandate

Vinge advises Adelis and other shareholders in connection with the sale of Logent

May 24, 2019 M&A

Vinge advises Adelis and other shareholders in connection with the sale of Logent to Stirling Square Capital Partners.

Logent is an independent contract logistics partner to logistics-intensive companies in Sweden and Norway. Logent has approximately 3,000 employees and operates along the whole logistics value chain within the business areas Warehousing, Transport Management, Customs, Ports, Staffing & Recruitment and Consulting.

Closing of the transaction is subject to the Swedish Competition Authority's approval. 

Vinge’s team consisted of partner Christina Kokko together with, among others, associates Samra Baytar, Manne Bergström andTove Lövgren Frisk and VDR Specialist Viktoria Owets. 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024